Researchers from KU Leuven, the University of California Davis Medical Center, the University of Cologne, and over 20 ...

Fungal infections are getting harder to treat as they grow more resistant to available drugs, according to research published ...

Olorofim, a novel antifungal agent, shows efficacy and tolerability in patients with invasive fungal diseases with limited ...

A new class of antifungals has been identified, potentially useful to treat the more than 300 million people worldwide who develop serious fungal infections. Fungal infections are most commonly ...

A recent study published in the journal Biomedicines aimed to determine the antifungal tolerance of Candida auris (C. auris) to all three classes of antifungal drugs commonly used to treat ...

Fungal infections are becoming more drug-resistant and harder to treat. When will the FDA approve new antifungals?

Kerydin is the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails. It inhibits protein synthesis by inhibition of an aminoacyl-transfer ribonucleic acid ...

No new classes of antifungal drugs have become available during the last 20 years, according to a study in the journal Drugs, and only one new agent from a known antifungal class has been approved ...

The FDA has approved Brexafemme, a Scynexis antifungal drug, for treating vaginal yeast infections. The drug is the biotech’s first FDA-approved product and it also represents the first new ...

Since the development of the first antifungals in the 1950s, four main antifungal classes have been indicated for the treatment of IFIs: polyenes, triazoles, echinocandins and pyrimidine analogues.

SCY-078 is an investigational antifungal agent that is a semi-synthetic derivative of the natural product enfumafungin.

Researchers have identified a new class of antifungals to treat the more than 300 million people worldwide who develop serious fungal infections. The research is described in the current issue of ...